Abciximab (ReoPro)-Induced Thrombocytopenia Diagnosed Through Measurement of Heparin-Dependent Antibody

다국어 초록 (Multilingual Abstract)

Abciximab (ReoPro) is an extremely potent inhibitor of the glycoprotein IIb/IIIa receptor. Its main application is
in the maintenance of coronary flow after suboptimal coronary intervention. Complications associated with this
drug include bleeding and severe thrombocytopenia. We report a case of severe thrombocytopenia secondary to
abciximab therapy for percutaneous coronary intervention in a 65-year-old woman suffering from an acute myocardial
infarction. Her platelet count dropped to 1,000/mm3 7 hours after abciximab administration and improved
with transfusion of 12 units of platelet concentrate the following day. The patient was diagnosed through measurement
of heparin-dependent antibodies and readministration of heparin.

다국어 초록 (Multilingual Abstract)

Abciximab (ReoPro) is an extremely potent inhibitor of the glycoprotein IIb/IIIa receptor. Its main application is
in the maintenance of coronary flow after suboptimal coronary intervention. Complications associated with this
drug include bleeding and severe thrombocytopenia. We report a case of severe thrombocytopenia secondary to
abciximab therapy for percutaneous coronary intervention in a 65-year-old woman suffering from an acute myocardial
infarction. Her platelet count dropped to 1,000/mm3 7 hours after abciximab administration and improved
with transfusion of 12 units of platelet concentrate the following day. The patient was diagnosed through measurement
of heparin-dependent antibodies and readministration of heparin.

참고문헌 (Reference)

1 The EPIC Investigators, "Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty" 330 : 956-961, 1994

2 Merlini PA, "Thrombocytopenia cause by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting" 109 : 2203-2206, 2004

3 Aster RH, "Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors" 4 : 678-679, 2006

4 Aster RH, "Thrombocytopenia associated with the use of GP IIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GP IIb/IIIa inhibitors" 4 : 678-679, 2006

5 Kim W, "The rescue use of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab; Reo-pro®) in high-risk patients with acute myocardial infarction underwent percutaneous coronary intervention" 31 : 492-499, 2001

6 Ferguson JJ, "Safe use of platelet GP IIb/IIIa inhibitors" 135 : S77-S89, 1998

7 The CAPTURE Investigators, "Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina" 349 : 1429-1435, 1997

8 The EPISTENT Investigators, "Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade" 352 : 87-92, 1998

9 The EPILOG Investigators, "Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization" 336 : 1689-1696, 1997

10 Topol EJ, "Platelet GP IIb-IIIa blockers" 353 : 227-231, 1999

11 Sane DC, "Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy" 36 : 75-83, 2000

12 Weimann G, "Glucosamine sulfate dose not cross-react with the antibodies of patients with heparin-induced thrombocytopenia" 66 : 195-199, 2001

13 Madan M, "Efficacy of abciximab readministration in coronary intervention" 85 : 435-440, 2000

14 Kelton JG, "Clinical usefulness of testing for a heparin-dependent plateletaggregating factor in patients with suspected heparin-associated thrombocytopenia" 103 : 606-612, 1984

15 Kereiakes DJ, "Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade" 140 : 74-80, 2000

16 Coller BS, "Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy" 92 : 2373-2380, 1995

17 Coller BS, "Anti-GP IIb/IIIa drugs: current strategies and future directions" 86 : 427-443, 2001

18 Butler R, "Acute severe thrombocytopenia after treat ment with abciximab" 83 : e5-, 2000

19 Berkowitz SD, "Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy" 95 : 809-813, 1997

20 김민환, "A Case of Abciximab Induced Acute Profound Thrombocytopenia Resulting in Compartment Syndrome of the Forearm from Massive Bleeding at the Brachial Artery Access Site" 대한심장학회 37 (37): 594-598, 2007